Clinical

Dataset Information

0

Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab


ABSTRACT: The main objective is to evaluate progression-free survival (PFS) at 4 months. The secondary objectives are to evaluate the objective response rate (OR) (= complete responses (CR) and partial responses (PR)) according to the RECIST v1.1 criteria, the progression-free survival (PFS), the overall survival (OS), the overall survival from the date of the first-line chemotherapy used on the metastatic disease, the treatment tolerance (NCI CTC AE V4 criteria, except for peripheral neurological toxicity (Lévi Scale)), the quality of life according to the EORTC QLQ-C30 criteria. The objectives of the biological study are to evaluate potentially predictive anti-EGFR and anti-VEGF response factors and CEC rates as predictive biomarkers for the efficacy of bevacizumab associated with chemotherapy in mCRC treatment.

DISEASE(S): Adenocarcinoma,Colorectal Cancer,Colorectal Neoplasms,Disease Progression

PROVIDER: 2113460 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2016-08-01 | E-GEOD-65021 | biostudies-arrayexpress
2018-01-10 | E-MTAB-5749 | biostudies-arrayexpress
2016-08-01 | GSE65021 | GEO
2022-01-19 | GSE138214 | GEO
2012-01-01 | E-GEOD-32048 | biostudies-arrayexpress
2016-12-15 | GSE91089 | GEO
| 2113482 | ecrin-mdr-crc
2022-08-22 | GSE209579 | GEO
2017-12-20 | E-MTAB-6214 | biostudies-arrayexpress
2011-01-07 | E-GEOD-25698 | biostudies-arrayexpress